
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal
(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7 per share in cash upfront, …